Garetosmab in fibrodysplasia ossificans progressiva : a randomized, double-blind, placebo-controlled phase 2 trial
© 2023. The Author(s)..
Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, adult patients with FOP were randomized to garetosmab, an activin A-blocking antibody (n = 20) or placebo (n = 24) in period 1 (28 weeks), followed by an open-label period 2 (28 weeks; n = 43). The primary end points were safety and for period 1, the activity and size of HO lesions. All patients experienced at least one treatment-emergent adverse event during period 1, notably epistaxis, madarosis and skin abscesses. Five deaths (5 of 44; 11.4%) occurred in the open-label period and, while considered unlikely to be related, causality cannot be ruled out. The primary efficacy end point in period 1 (total lesion activity by PET-CT) was not met (P = 0.0741). As the development of new HO lesions was suppressed in period 1, the primary efficacy end point in period 2 was prospectively changed to the number of new HO lesions versus period 1. No placebo patients crossing over to garetosmab developed new HO lesions (0% in period 2 versus 40.9% in period 1; P = 0.0027). Further investigation of garetosmab in FOP is ongoing. ClinicalTrials.gov identifier NCT03188666.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Nature medicine - 29(2023), 10 vom: 28. Okt., Seite 2615-2624 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial, Phase II |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 23.11.2023 published: Print-Electronic ClinicalTrials.gov: NCT03188666 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-023-02561-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362668701 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362668701 | ||
| 003 | DE-627 | ||
| 005 | 20231226091720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-023-02561-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362668701 | ||
| 035 | |a (NLM)37770652 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Rocco, Maja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Garetosmab in fibrodysplasia ossificans progressiva |b a randomized, double-blind, placebo-controlled phase 2 trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 23.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03188666 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, adult patients with FOP were randomized to garetosmab, an activin A-blocking antibody (n = 20) or placebo (n = 24) in period 1 (28 weeks), followed by an open-label period 2 (28 weeks; n = 43). The primary end points were safety and for period 1, the activity and size of HO lesions. All patients experienced at least one treatment-emergent adverse event during period 1, notably epistaxis, madarosis and skin abscesses. Five deaths (5 of 44; 11.4%) occurred in the open-label period and, while considered unlikely to be related, causality cannot be ruled out. The primary efficacy end point in period 1 (total lesion activity by PET-CT) was not met (P = 0.0741). As the development of new HO lesions was suppressed in period 1, the primary efficacy end point in period 2 was prospectively changed to the number of new HO lesions versus period 1. No placebo patients crossing over to garetosmab developed new HO lesions (0% in period 2 versus 40.9% in period 1; P = 0.0027). Further investigation of garetosmab in FOP is ongoing. ClinicalTrials.gov identifier NCT03188666 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Forleo-Neto, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Pignolo, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Keen, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Orcel, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Funck-Brentano, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Roux, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Kolta, Sami |e verfasserin |4 aut | |
| 700 | 1 | |a Madeo, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Bubbear, Judith S |e verfasserin |4 aut | |
| 700 | 1 | |a Tabarkiewicz, Jacek |e verfasserin |4 aut | |
| 700 | 1 | |a Szczepanek, Małgorzata |e verfasserin |4 aut | |
| 700 | 1 | |a Bachiller-Corral, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Cheung, Angela M |e verfasserin |4 aut | |
| 700 | 1 | |a Dahir, Kathryn M |e verfasserin |4 aut | |
| 700 | 1 | |a Botman, Esmée |e verfasserin |4 aut | |
| 700 | 1 | |a Raijmakers, Pieter G |e verfasserin |4 aut | |
| 700 | 1 | |a Al Mukaddam, Mona |e verfasserin |4 aut | |
| 700 | 1 | |a Tile, Lianne |e verfasserin |4 aut | |
| 700 | 1 | |a Portal-Celhay, Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkar, Neena |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Peijie |e verfasserin |4 aut | |
| 700 | 1 | |a Musser, Bret J |e verfasserin |4 aut | |
| 700 | 1 | |a Boyapati, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadi, Kusha |e verfasserin |4 aut | |
| 700 | 1 | |a Mellis, Scott J |e verfasserin |4 aut | |
| 700 | 1 | |a Rankin, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Economides, Aris N |e verfasserin |4 aut | |
| 700 | 1 | |a Trotter, Dinko Gonzalez |e verfasserin |4 aut | |
| 700 | 1 | |a Herman, Gary A |e verfasserin |4 aut | |
| 700 | 1 | |a O'Meara, Sarah J |e verfasserin |4 aut | |
| 700 | 1 | |a DelGizzi, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Weinreich, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Yancopoulos, George D |e verfasserin |4 aut | |
| 700 | 1 | |a Eekhoff, E Marelise W |e verfasserin |4 aut | |
| 700 | 1 | |a Kaplan, Frederick S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 29(2023), 10 vom: 28. Okt., Seite 2615-2624 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:10 |g day:28 |g month:10 |g pages:2615-2624 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-023-02561-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 10 |b 28 |c 10 |h 2615-2624 | ||